Abstract
RATIONALE: Toll-like receptors (TLRs) have been shown to modulate allergic immune responses. The safety and efficacy of VTX-1463_a novel, small-molecule, TLR8 agonist given once weekly intranasally_was assessed in allergic rhinitis (AR) subjects exposed to allergen in the Vienna Challenge Chamber (VCC).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
